Charu Aggarwal, MD, MPH

Charu Aggarwal, MD, MPH, is a physician leader in Airways Malignancies Research, director of Precision Oncology Innovation at Penn Center for Cancer Care Innovation, section chief of Head & Neck and Thoracic Cancers, Hematology-Oncology, and the Leslye M. Heisler Professor for Lung Cancer Excellence at Penn Medicine in Philadelphia, Pennsylvania.

Articles by Charu Aggarwal, MD, MPH

Drs Jared Weiss and Charles Rudin sitting behind a panel desk, smiling at camera.

Choosing the Appropriate Treatment in the Second Line Setting in SCLC

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD,Vivek Subbiah, MD,Jared Weiss, MD

August 11th 2022

Experts provide insights on choosing the optimal therapy in patients with small cell lung cancer in the second line and beyond.

Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD,Vivek Subbiah, MD,Jared Weiss, MD

August 2nd 2022

Dr Jared Weiss presents the profile of a 70-year-old male patient with SCLC who received chemotherapy in the second line setting for discussion to the panel.

Drs Taofeek Owonikoko and Vivek Subbiah sitting behind a panel desk, smiling at camera.

Lurbinectedin for SCLC Treatment in the Second-Line Setting

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD,Vivek Subbiah, MD,Jared Weiss, MD

August 2nd 2022

Dr Vivek Subbiah explains the clinical trial data that led to the approval of lurbinectedin for SCLC treatment.

Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD, PhD,Vivek Subbiah, MD,Jared Weiss, MD

July 29th 2022

The panel discusses the second line treatment options in SCLC and how they choose among the various options based on patient and disease characteristics.

Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD, PhD,Vivek Subbiah, MD,Jared Weiss, MD

July 29th 2022

Vivek Subbiah, MD, MPH, presents the patient profile of a 60-year-old man with SCLC who progressed on frontline therapy.

Ongoing Trials and Real-World Studies in Frontline SCLC

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD, PhD,Vivek Subbiah, MD,Jared Weiss, MD

July 18th 2022

Dr Charles Rudin highlights other notable clinical trials and real-world studies in patients with SCLC in the frontline setting.

IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD, PhD,Vivek Subbiah, MD,Jared Weiss, MD

July 18th 2022

Dr Charu Aggarwal shares data from the IMpower133 trial of atezolizumab plus chemotherapy for SCLC, and how to select the appropriate frontline therapy.

Management of Adverse Events Associated with Durvalumab + Chemotherapy

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD,Vivek Subbiah, MD,Jared Weiss, MD

July 11th 2022

Vivek Subbiah, MD, analyzes adverse events observed with durvalumab plus chemotherapy in patients with SCLC and how they can be managed.

Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy

ByTaofeek K. Owonikoko, MD, PhD,Charu Aggarwal, MD, MPH,Charles M. Rudin, MD, PhD,Vivek Subbiah, MD,Jared Weiss, MD

July 11th 2022

Jared Weiss, MD, reviews data from the CASPIAN trial of durvalumab plus chemotherapy in patients with extensive-stage small cell lung cancer.

Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD, PhD,Vivek Subbiah, MD,Jared Weiss, MD

July 6th 2022

Charu Aggarwal, MD, MPH, presents the profile of a patient with small cell lung cancer with brain metastases to spark a discussion on treatment approaches in the frontline setting.

Progress in the Treatment and Management of SCLC

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD, PhD,Vivek Subbiah, MD,Jared Weiss, MD

July 6th 2022

The panel discusses how the field of small cell lung cancer treatment has changed in recent years.

Use of the TNM Staging System in SCLC

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD, PhD,Vivek Subbiah, MD,Jared Weiss, MD

June 27th 2022

Charles Rudin, MD, PhD, explains the prognostic staging systems used for small cell lung cancer.

close-up of Taofeek Owonikoko, MD, PhD, and Vivek Subbiah, MD, smiling at camera

Overview of SCLC and Importance of Early Diagnosis

ByCharu Aggarwal, MD, MPH,Taofeek K. Owonikoko, MD, PhD,Charles M. Rudin, MD, PhD,Vivek Subbiah, MD,Jared Weiss, MD

June 27th 2022

Drs Owonikoko and Weiss provide a brief overview of small cell lung cancer and the vital importance of an early diagnosis to improve patient outcomes.

Charu Aggarwal, MD, MPH

Articles by Charu Aggarwal, MD, MPH

Choosing the Appropriate Treatment in the Second Line Setting in SCLC

Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

Lurbinectedin for SCLC Treatment in the Second-Line Setting

Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy

Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

Ongoing Trials and Real-World Studies in Frontline SCLC

IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy

Management of Adverse Events Associated with Durvalumab + Chemotherapy

Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy

Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases

Progress in the Treatment and Management of SCLC

Use of the TNM Staging System in SCLC

Overview of SCLC and Importance of Early Diagnosis

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Meta-Analysis Characterizes Nivolumab/Ipilimumab Hyperprogression in Renal Medullary Carcinoma

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma